跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,428 条关于
“QUILT 502”
全部
5,428
临床试验
2,533
药物
2,279
机构
10
资讯
606
去年
ImmunityBio Initiates Phase I Trial of CD19-Targeted haNK Cell Therapy for NHL in South Africa
去年
ImmunityBio Partners with nCartes to Streamline Clinical Trial Data Collection Through EMR Automation
去年
Quilt Health Secures $6M Seed Funding to Modernize Clinical Trial Access for Complex Diseases
去年
Anktiva Plus BCG Shows High Response in BCG-Unresponsive NMIBC
3个月前
FDA Updates Draft Guidance on Drug and Device Manufacturer Communications with Payors, Incorporating PIE Act Provisions
去年
ImmunityBio Initiates Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma
去年
ImmunityBio's Anktiva Pursues European and UK Approval for BCG-Unresponsive Bladder Cancer
去年
ImmunityBio Launches Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma
去年
ImmunityBio's Anktiva Receives EMA Review for Bladder Cancer Treatment
去年
ANKTIVA Receives Permanent J-Code from CMS, Streamlining Reimbursement for Bladder Cancer Treatment
第 1 页,共 61 页
上一页
下一页